Update on timing of preliminary results

Avacta Group plc

("Avacta" or the "Group" or the "Company")

Update on timing of preliminary results announcement

LONDON and PHILADELPHIA - May 27, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces that the preliminary results for year ended December 31, 2024 will now be published on June 4, 2025 as the Group's auditors have been unable to finalise the audit work connected to the disposal of Launch Diagnostics, which completed post period end, by the originally planned date of May, 29 2025. The Group was notified of this development on May 23, 2025. 

There is no impact to Avacta's financial position and cash runway.

Christina Coughlin, Chief Executive Officer and Brian Hahn, Chief Financial Officer will now deliver the planned live presentation via Investor Meet Company at 11:00 BST on June 4, 2025.

The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:

https://www.investormeetcompany.com/avacta-group-plc/register-investor. 

Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via the Investor Meet Company dashboard up until June 4 at 09:00 BST, or at any time during the live presentation.

The Company will also post the results presentation on its website at the following page: https://avacta.com/investors/investor-resources/.

-Ends -

About Avacta - www.avacta.com

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

About the pre|CISION® Platform

The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.